drugset / Trial / NCT01000064
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can help with attention deficits due to traumatic brain injury (TBI). Vyvanse is currently approved for the treatment of Attention-Deficit/Hyperactivity (ADHD). The exact effects this drug may have on attention deficits caused by TBI are not known, but we expect that Vyvanse will be of some help in treating those types of problems as well. The study will utilize functional magnetic resonance imaging (fMRI) methods, as well as neurobehavioral measures, to elucidate neural mechanisms of response.
Timeline
- Start
- 2009-10
- Primary completion
- 2013-12
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 30 mg | — |
| Comparator | Lisdexamfetamine Dimesylate | Small molecule | 70 mg | — |